Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress

The proteasome inhibitor bortezomib has proven to be invaluable in the treatment of myeloma. By exploiting the inherent high immunoglobulin protein production of malignant plasma cells, bortezomib induces endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), resulting in myeloma...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallington-Beddoe, Craig T., Bennett, Melissa K., Vandyke, Kate, Davies, Lorena, Zebol, Julia R., Moretti, Paul A.B., Pitman, Melissa R., Hewett, Duncan R., Zannettino, Andrew C.W., Pitson, Stuart M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546428/
https://www.ncbi.nlm.nih.gov/pubmed/28467788
http://dx.doi.org/10.18632/oncotarget.17115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546428/
https://www.ncbi.nlm.nih.gov/pubmed/28467788
http://dx.doi.org/10.18632/oncotarget.17115

Ejemplares similares